| Literature DB >> 27456854 |
Anne Hecksteden1, Petra Leidinger2, Christina Backes3, Stefanie Rheinheimer2, Mark Pfeiffer4, Alexander Ferrauti5, Michael Kellmann5,6, Farbod Sedaghat-Hamedani7, Benjamin Meder7, Eckart Meese2, Tim Meyer1, Andreas Keller8.
Abstract
BACKGROUND: The dependency of miRNA abundance from physiological processes such as exercises remains partially understood. We set out to analyze the effect of physical exercises on miRNA profiles in blood and plasma of endurance and strength athletes in a systematic manner and correlated differentially abundant miRNAs in athletes to disease miRNAs biomarkers towards a better understanding of how physical exercise may confound disease diagnosis by miRNAs.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27456854 PMCID: PMC4960671 DOI: 10.1186/s12967-016-0974-x
Source DB: PubMed Journal: J Transl Med ISSN: 1479-5876 Impact factor: 5.531
Fig. 1Study set-up. Horizontal arrays represent paired analyses, vertical arrows unpaired statistical calculations
Fig. 2Principal component analysis. a presents PCA of all data points (red blood samples, blue plasma samples). b contains only blood and c only plasma samples (orange strength athletes, blue endurance athletes)
Fig. 3Hierarchical clustering of all samples. The heatmap indicates that substantial differences between blood and plasma are observed but also profiles between endurance and strength athletes generally cluster together
Fig. 4Box plots of two selected examples in the eight tested groups. a The first miR-650 is only expressed in blood of strength athletes. b The second miR-140-5p is up-regulated in blood and plasma of strength as well as endurance athletes
Fig. 5Running sum that highlights “acute myocardial infarction” miRNAs to be significantly changed in strength versus power athletes
Fig. 6Network analysis of target genes. For miRNAs dys-regulated between strength and endurance athletes we mapped target genes by functional experimental analysis. The most central gene was VEGFA, which is regulated by five miRNAs. As the table below the figure highlights, all miRNAs targeting VEGFA are up-regulated in endurance athletes
Fig. 7Effect of training. The provided examples indicate that also short-time influences of miRNAs to training are observed
Pair-wise comparisons of prior- and post training for endurance and strength athletes in blood and plasma
| miRNA | Plasma strength p | Plasma strength AUC | Blood strength p | Blood strength AUC | Plasma endurance p | Plasma endurance AUC | Blood endurance p | Blood endurance AUC |
|---|---|---|---|---|---|---|---|---|
| hsa-miR-17-5p | 0.1017 | 0.39 | 0.7784 | 0.53 | 0.8919 | 0.47 |
| 0.26 |
| hsa-miR-454-3p | 0.4262 | 0.52 | 0.5771 | 0.55 | 0.9280 | 0.48 |
| 0.33 |
| hsa-miR-20a-5p | 0.3969 | 0.43 | 0.7346 | 0.44 | 0.8167 | 0.56 |
| 0.29 |
| hsa-miR-590-5p | 0.1679 | 0.39 |
| 0.27 | 0.4055 | 0.58 | 0.2603 | 0.36 |
| hsa-miR-3200-3p | 0.1099 | 0.67 |
| 0.35 | 0.3392 | 0.59 |
| 0.26 |
| hsa-miR-29c-3p |
| 0.67 |
| 0.34 | 0.6568 | 0.55 | 0.7085 | 0.50 |
| hsa-miR-27b-3p | 0.8400 | 0.52 | 0.3308 | 0.54 | 0.2059 | 0.57 |
| 0.27 |
| hsa-miR-513a-5p | 0.7051 | 0.54 | 0.3726 | 0.42 |
| 0.25 | 0.1464 | 0.60 |
| hsa-miR-26b-5p | 0.3362 | 0.41 | 0.1040 | 0.65 | 0.4129 | 0.58 |
| 0.31 |
| hsa-miR-1246 |
| 0.86 | 0.9294 | 0.60 | 0.2875 | 0.55 | 0.6481 | 0.59 |
The significance values are shown along with the AUC values. Significant findings are highlighted in italics
KEGG and GO enrichment analysis
| Category | Database | Target genes on category | Expectation value | Enrichment | p value |
|---|---|---|---|---|---|
| Melanoma | KEGG | 17 | 3.7 | 4.6 | 3.10E−06 |
| Bladder cancer | KEGG | 13 | 2.4 | 5.4 | 1.36E−05 |
| Cell cycle | KEGG | 19 | 5.3 | 3.6 | 1.83E−05 |
| Glioma | KEGG | 15 | 3.4 | 4.4 | 1.83E−05 |
| G1_phase(4) & mitotic_G1_phase(5) | GO | 11 | 1.3 | 8.3 | 2.34E−05 |
| Viral carcinogenesis | KEGG | 20 | 6.0 | 3.3 | 2.59E−05 |
| Pancreatic cancer | KEGG | 16 | 4.1 | 4.0 | 2.72E−05 |
| Chronic myeloid leukemia | KEGG | 17 | 4.6 | 3.7 | 3.04E−05 |
| Non-small cell lung cancer | KEGG | 12 | 3.1 | 3.9 | 5.86E−04 |
| p53 signaling pathway | KEGG | 11 | 3.2 | 3.4 | 3.44E−03 |
| Thyroid cancer | KEGG | 6 | 1.4 | 4.3 | 2.67E−02 |
| Biological_phase(2) | GO | 15 | 4.9 | 3.1 | 4.68E−02 |
| Cell_cycle_phase(3)&mitotic_cell_cycle_phase(4) | GO | 15 | 4.6 | 3.3 | 4.68E−02 |
| Cell_maturation(5) | GO | 14 | 4.2 | 3.3 | 4.68E−02 |
| Regulation_of_fibroblast_proliferation(5) | GO | 12 | 3.3 | 3.6 | 4.68E−02 |
| Positive_regulation_of_fibroblast_proliferation(5) | GO | 10 | 2.3 | 4.3 | 4.68E−02 |
| Interphase(4) | GO | 9 | 1.9 | 4.8 | 4.68E−02 |
| Hair_follicle_morphogenesis(4) | GO | 7 | 1.2 | 6.0 | 4.68E−02 |
Significant categories containing at least three times more genes than expected by chance. Provided are the category name, the database where data have been extracted, the number of targets genes of the 63 miRNAs of this category, the expected number of genes given the 2098 background genes, the enrichment factor, and the p value following adjustment for multiple testing